Board of Directors
Brad Thompson, PhD
Dr. Thompson has held the positions of Chairman of the Board, President and Chief Executive Officer of Oncolytics Biotech Inc. since April 1999. He has provided leadership to various organizations within the biotechnology sector for more than twenty years. Prior to his role with Oncolytics, Dr. Thompson was the Chief Executive Officer of SYNSORB Biotech from 1994 to 1999. From 1983 to 1994, Dr. Thompson worked in a senior role at the Alberta Research Council. He is the current Chairman of BIOTECanada. He received his PhD from the University of Western Ontario in the Department of Microbiology and Immunology.
Bob Schultz, FCA
Mr. Schultz was the Chairman and Director of Rockwater Capital Corporation, formerly McCarvill Corporation (a financial services company) from 2001 to 2007. He held the position Chairman and Chief Executive Officer of Merrill Lynch Canada from August 1998 until his retirement on May 1, 2000. Prior to this appointment, Mr. Schultz was Chief Executive Officer at Midland Walwyn since 1990. Since joining the investment industry in 1971, Mr. Schultz has held a variety of senior positions, and has participated on various industry-related boards and committees including Director and Chairman of the Investment Dealers Association of Canada.
Matt Coffey, PhD
A co-founder of Oncolytics Biotech Inc., Dr. Coffey’s current responsibilities include directing the Company's research and development efforts, and integrating these efforts into an effective clinical trial program and intellectual property position for the Company. Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey has held the position of Chief Operations Officer of the Corporation since December 2008, Chief Operating Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.
Mr. Dinning has been the Chair of Western Financial Group since September 2004. He was Executive Vice President of TransAlta Corporation (a power generation and wholesale marketing company) from 1997 to 2004 and served as Member of the Alberta Legislative Assembly from 1986 to 1997. Of note was his term as Provincial Treasurer from 1992 to 1997. Mr. Dinning is the Chairman of the Board of Liquor Stores NA Ltd and Export Development Canada and serves as Director of other public and private companies. He is the Chancellor of the University of Calgary
Ed Levy, PhD
Dr. Levy has been an adjunct professor at the W. Maurice Young Centre for Applied Ethics at the University of British Columbia since retiring from QLT Inc. in 2002. From 1988 to 2002, Dr. Levy was with Vancouver-based biotechnology company QLT Inc., most recently as Senior Vice President from 1998. In these roles, he was primarily responsible for negotiating and managing QLT’s strategic alliances, leading strategic planning and overseeing the company’s intellectual property. Dr. Levy served on the board of BIOTECanada from 1999 to 2002, and he has served on the boards of several technology companies and not-for-profits. Dr. Levy holds a PhD in the History and Philosophy of Science from Indiana University and taught philosophy of science at UBC from 1967 to 1988.
J. Mark Lievonen, CA
Mr. Lievonen has held the position of President of Sanofi Pasteur Limited, a vaccine development, manufacturing and marketing company, since October 1998 and has held various other positions with Sanofi Pasteur Limited and its predecessors since 1983. Mr. Lievonen currently serves on a number of industry and community boards and councils including the Ontario Institute for Cancer Research, the Public Policy Forum, Markham Stouffville Hospital, Ontario-Quebec Private Sector Advisory Committee, York University and the Ontario Investment and Trade Advisory Committee. He is a former Chair of the Ontario Genomics Institute and BIOTECanada, and former Co-Chair of the Centre for the Advancement of Health Innovations. He was named a Chevalier de l'Ordre National de Mérite by the government of France in 2007.
Fred A. Stewart, QC
Mr. Stewart is the former President of Fred Stewart & Associates Inc. (a government and corporate relations consulting company), which he founded in 1996. Prior to that, Mr. Stewart was associated with a major Alberta law firm. He was a member of the Alberta Legislative Assembly, and during two terms from 1986 to 1993, he served as Minister of Technology, Research and Telecommunications and Government House Leader. Earlier, Mr. Stewart practised corporate and commercial law for over twenty years in Calgary in a firm of which he was a founding partner.
Ger van Amersfoort
Mr. van Amersfoort was the President and Chief Executive Officer of Novartis Canada, a pharmaceutical company with in excess of $1 billion in annual sales and a workforce of 1,500, until his retirement in 2001. Before joining Novartis, he was President and Chief Executive Officer of the U.K. SmithKline Beecham operations from 1997 until managing the merger with Novartis in 1999. From 1990 to 1997, Mr. van Amersfoort headed up SmithKline Beecham operations in Canada as President and Chief Executive Officer. Prior to that, he held managing director positions with Beecham and The Boots Company, and sales positions with Bristol Myers in Holland. He is a recipient of the Paul Harris Medal and the Commemorative Medal of the Queen for outstanding services to the community. He has served on the Board of the Pharmaceutical Manufacturers Association of Canada (now Canada's Research Based Pharmaceutical Companies, Rx and D) for more than nine years, serving as chairman in 1996.
Learn about our lead product, REOLYSIN®, a proprietary formulation of the reovirus.